Loading
The alphabet soup of myeloma treatment: V (bortezomib, Velcade), R (lenalidomide, Revlimid), d (dexamethasone), Dara (daratumumab), Isa (isatuximab), K (carfilzomib). Dara-VRd, a four-drug quadruplet, is now the standard first treatment for most patients.
VRd was the standard triplet for a decade (SWOG S0777). Adding a CD38 antibody made quadruplets standard: Dara-VRd before and after autologous transplant (PERSEUS) and in transplant-ineligible patients (CEPHEUS), Isa-VRd in IMROZ, with Dara-Rd (MAIA) for frailer patients. Bortezomib causes neuropathy and is often dropped after induction; lenalidomide continues as maintenance. MRD negativity rates above 60% with quadruplets are prompting trials of MRD-guided de-escalation and of CAR-T or bispecifics in place of transplant (CARTITUDE-5/6).
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Bortezomib.
Shares Undetectable MRD (uMRD / MRD-negative), Newly diagnosed multiple myeloma, transplant-ineligible, Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Bortezomib, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab, Bortezomib, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Bortezomib, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Newly diagnosed multiple myeloma, transplant-eligible, Bortezomib, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab, Lenalidomide, Multiple myeloma.
Shares Daratumumab, Bortezomib, Lenalidomide, Multiple myeloma.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Daratumumab, Lenalidomide, Multiple myeloma.